Hepatitis B Control Country Profile 2015
Country Profile 2015 WPR/2016/EPI/003 © World Health Organization 2016 All rights reserved. CONTENTS Country Profiles American Samoa 3 Australia 4 Brunei Darussalam 5 Cambodia 6 China 7 Hong Kong SAR (China) 8 Macao SAR (China) 9 Commonwealth of the Northern Mariana Islands 10 Cook Islands 11 Fiji 12 French Polynesia 13 Guam 14 Japan 15 Kiribati 16 Lao People’s Democratic Republic 17 Malaysia 18 Federated States of Micronesia 19 Mongolia 20 Nauru 21 New Caledonia 22 New Zealand 23 Niue 24 Palau 25 Papua New Guinea 26 Philippines 27 Republic of Korea 28 Republic of the Marshall Islands 29 Samoa 30 Singapore 31 Solomon Islands 32 Tokelau 33 Tonga 34 Tuvalu 35 Vanuatu 36 Viet Nam 37 Wallis and Futuna 38 Regional Progress: Hepatitis B Vaccination Coverage, 1990—2015 1 Regional Progress: Status of the 2017 Hepatitis B Control Milestone of <1% HBsAg Prevalence among 5 year old children 2 Regional Progress Hepatitis B vaccination coverage, 1990 – 2015 0 10 20 30 40 50 60 70 80 90 100 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 V ac ci n at io n c o ve ra ge ( % ) Year of birth Hepatitis B vaccine birth dose Hepatitis B vaccine 3rd dose Source: WHO and UNICEF Joint Reporting Form on Immunization 1 Regional Progress Regional Progress: Status of the 2017 Hepatitis B Control Milestone of <1% HBsAg Prevalence among 5 year old children The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. © WHO Regional Office for the Western Pacific 2016. All rights reserved 2 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 3 AMERICAN SAMOA Total population (2015) 55 538 Births (2011) 1 287 Surviving infants (2011) 1 278 Urban population (2015) 87% HepB3 introduced nationwide 1986-1987 HepB birth dose introduced 1991 Current schedule 0, 1 month, 12 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1990 National 3–4 years 95 not reported 82% not reported Mahoney Pac Hth Dialog 1996 1995 National 7-8 years 432 75% 91% not reported Bialek ISVHLD P351 2006 1996 National 7-8 years 435 not reported 87% not reported Mahoney Pac Hth Dialog 1996 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1991 Tutuila 3-4 years Community based 93 2.2% Mahoney JID 2009 1995 Nationwide 7-8 years Community based 432 0.5% Bialek ISVHLD P351 2006 2011 Nationwide 6 years School based 562 0.2% Govt American Samoa 2012 Status of verifying prevalence targets Verification started: February 2013 Decision: <1% in children Decision date: October 2014 99.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2015 revision; Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 4 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown AUSTRALIA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2007 National 12 months 280 874 not reported 94% 92% From National Health Insurance covering 99% of population Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2002 Nationwide 1-9 years Hospital based 249 0.4% (0.0% - 2.2%) Gidding Vaccine 2007 Total population (2015) 23 968 973 Births (2015) 317 650 Surviving infants (2015) 314 448 Urban population (2015) 89% HepB3 introduced nationwide 2000 HepB birth dose introduced 2000 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-Hib-HepB-IPV Status of verifying prevalence targets Verification started: June 2012 Decision: <1% in children Decision date: December 2012 99.1% 0.9% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic ts 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2015 revision; Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 5 BRUNEI DARUSSALAM Total population (2015) 417 200 Births (2015) 6 699 Surviving infants (2015) 6 455 Urban population (2015) 77% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-Hib-HepB-IPV Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2011 National 8-9 years School based 4513 0.09% MoH Brunei 2012 Status of verifying prevalence targets Verification started: March 2013 Decision: <1% in children Decision date: June 2013 99.8% 0.1% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 6 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown CAMBODIA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2005 National 12-23 months 1517 not reported not reported 78% DHS Survey 2009 National 12-23 months 1068 61% not reported 56% Cambodia Socio-Economic Survey 2009 (confirmation method only by card) 2010 National 12-23 months 1614 73% 84% 84% DHS Survey:HepB BD 73%, HepB3 85%, DTP3 85% by 12 months 2014 National 12-23 months 1460 83% 84% 84% DHS Survey:HepB BD 83%, HepB3 82%, DTP3 82% by 12 months Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2001 Kg Chhnang 9-17 months Hospital based 900 2.7% Report MoH/PATH/AIHI 2006 Nationwide 5 years Community based 1558 3.5% (2.4% - 4.8%) Soeung AMTH 2009 2011 Urban, Rural, Remote 4-5 years Community based 2429 0.3%, 1.4%, 3.5% Mao Vaccine 2013 Total population (2015) 14 892 374 Births (2015) 381 245 Surviving infants (2015) 344 014 Urban population (2015) 93% HepB3 introduced nationwide 2005 HepB birth dose introduced 2005 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 54.0% 17.0% 29.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 7 CHINA Total population (2015) 1 374 620 000 Births (2015) 16 550 000 Surviving infants (2014) 16 152 165 Urban population (2015) 21% HepB3 introduced nationwide 1992 HepB birth dose introduced 1992 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2004 National 12-23 months 171 188 not reported 85% not reported The National EPI Evaluation Report 2004 (Confirmation method by card only); 90% HepB3 by 12 months 2006 National 1 year 3636 93% 83% not reported Liang JID 2009; 2005 birth cohort 2008 National 12-23 months 9762 not reported 93% 91% Analysis Report of National Health Services Survey in China Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2006 Nationwide 1-4 years Community based 16 376 1.0% (0.8% - 1.2%) Liang Vaccine 2009 2006 Nationwide 5 years Community based 2215 1.1% (0.4% - 1.8%) Liang JID 2009 2006 Nationwide 6 years Community based 2356 0.9% (0.4% - 1.5%) Liang JID 2009 Status of verifying prevalence targets Verification started: February 2012 Decision: <1% in children Decision date: June 2012 96.3% 3.7% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 8 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown HONG KONG SAR (CHINA) Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2009 National 2-5 years 6248 not reported ≥99.5% >99.8% MoH Hong Kong 2011 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2006 Nationwide 1-4 years Laboratory based 196 1% MoH Hong Kong 2011 2009 Nationwide 12-15 years School based 1913 0.8% (0.4% - 1.2%) MoH Hong Kong 2011 Total population (2015) 7 305 700 Births (2015) 59 901 Surviving infants (2015) no data Urban population (2015) 95% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Status of verifying prevalence targets Verification started: February 2011 Decision: <1% in children Decision date: July 2011 100.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 9 MACAO SAR (CHINA) Total population (2015) 646 800 Births (2015) 7 055 Surviving infants (2015) 7 055 Urban population (2015) 100% HepB3 introduced nationwide 1984 HepB birth dose introduced 1989 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2003 National 6-9 years School based 437 0% (0% - 0.7%) MoH Macao 2008 Status of verifying prevalence targets Verification started: April 2008 Decision: <1% in children Decision date: August 2008 100.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * 10 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown COMMONWEALTH OF THE NORTHERN MARIANA ISLANDS Total population (2015) 55 070 Births (2011) 1 025 Surviving infants (2011) 1 038 Urban population (2015) 89% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 6 weeks, 6 months HepB3 type DTP-HepB-IPV Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1995 National 3-4 years 200 not reported 94% not reported Mahoney Pac Hth Dialog 1996 2005 National 19-35 months 295 100% 94% not reported Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1994 Saipan 3-4 years Health facility 200 0.5% Durand Pac Hlth Dial 1996 2014 Nationwide 6 years School based 804 0.0% CNMI Healthcare Corp. 2015 Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 100.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2015 revision; Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 11 COOK ISLANDS Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2012 7 of 11 islands 6 years School based 265 0% MoH Cook Islands 2013 Total population (2015) 15 052 Births (2015) 234 Surviving infants (2015) 232 Urban population (2015) 56% HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 6 weeks, 3 months, 5 months HepB3 type DTP-Hib-HepB Status of verifying prevalence targets Verification started: January 2013 Decision: <1% in children Decision date: October 2013 99.6% 0.4% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * 12 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown FIJI Total population (2015) 933 073 Births (2015) 20 236 Surviving infants (2015) 20 072 Urban population (2015) 75% HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1999 National 12-23 months not reported not reported 94% 92% Fiji National EPI Survey 2005 National 12-23 months 630 not reported 92% 83% Fiji Immunization Coverage Survey Report 2008 National 15-26 months 1200 86% 99% 99% Fiji National Immunisation Coverage Survey Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1998 Large Towns 12-24 months Hospital based 285 0.7% Wilson Vaccine 2000 2008 Sub-national 6 months-5 years Community based 428 0% WHO:RS/2009/GE/23(JPN) Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 99.8% 0.2% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 13 FRENCH POLYNESIA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1988 Austral Island 0-11 months Community based 957 2.1% B Trans R Soc Trop 1990 2013-2014 Nationwide 6-7 years School based 1196 0.0% (0.0%-0.5%) Patel Vaccine 2016 Total population (2015) 271 800 Births (2015) 4 146 Surviving infants (2015) no data Urban population (2015) 54% HepB3 introduced nationwide 1992 HepB birth dose introduced 1992 Current schedule 0, 2 months, 10 months HepB3 type DTP-Hib-HepB-IPV Status of verifying prevalence targets Verification started: February 2016 Decision: <1% in children Decision date: October 2016 99.0% 1.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * 14 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown GUAM Total population (2015) 161 785 Births (2015) 3 367 Surviving infants (2015) 3 319 Urban population (2015) 56% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 1-2 months, 6-18 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2015 National 6 years School based 1484 0.0% Guam DoH & Social Services 2015 Status of verifying prevalence targets Verification started: October 2015 Decision: <1% in children Decision date: July 2016 87.2% 0.6% 12.2% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 15 JAPAN Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1989 Okinawa 1-4 years School based 1529 0.1% Hayashi Int J Epi 1990 1995-1996 Nationwide 16-19 years Blood Donors 107 879 0.4% (0.4% - 0.5%) Furusyo AMTM 1998 1995-2000 Nationwide 16-19 years Blood Donors 582 415 0.23% (0.22% - 0.24%) Tanaka Intervirol 2004 2009 Iwate prefecture 5-9 years School based 17 363 0.0% (0.00%-0.04%) Tanaka Intervirol 2011 Total population (2015) 126 942 000 Births (2015) 1 037 064 Surviving infants (2015) 1 013 979 Urban population (2015) 100% HepB3 introduced nationwide Scheduled to start in Oct 2016 HepB birth dose introduced If born to HBsAg+ mothers Current schedule 2 months, 3 months, 7 months HepB3 type Monovalent Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 99.8% 0.2% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 16 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown KIRIBATI Total population (2015) 114 104 Births (2015) 3 340 Surviving infants (2015) 3 180 Urban population (2015) 44% HepB3 introduced nationwide 1995 HepB birth dose introduced 1990 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2009 National 48-59 months 181 not reported not reported 32% DHS Survey; by 12 months 2009 National 36-47 months 200 not reported not reported 42% DHS Survey; by 12 months 2009 National 24-35 months 202 not reported not reported 50% DHS Survey; by 12 months 2009 National 12-23 months 233 not reported 61% 61% DHS Survey: HepB3 58%, DTP3 58% by 12 months Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1998 Large Towns 12-24 months Hospital based 156 3.8% Wilson Vaccine 2000 2014 National 5-9 years Community based 1249 3.3% MoH Kiribati 2015 Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 81.9% 16.4% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 17 LAO PEOPLE’S DEMOCRATIC REPUBLIC Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2006 National 12-23 months 828 not reported not reported 41% Lao PDR Multiple Indicator Cluster Survey 2006 Final Report; DTP3 32% by 12 months 2011-2012 National 12-23 months 2141 37% 56% 56% Lao Social Indicator Survey (LSIS), (MICS / DHS Survey): HepB BD 37%, HepB3 52%, DTP3 52% by 12 months 2015 National 12-23 months 5981 72% 81% 81% National Immunization Survey Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2012 National 5-9 years Community based 965 1.7% (0.8%-2.6%) Xeuatvongsa PloS ONE 2014 Total population (2015) 6 949 000 Births (2015) 194 026 Surviving infants (2015) 183 962 Urban population (2015) 39% HepB3 introduced nationwide 2001 HepB birth dose introduced ~2004 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 12.8% 5.7% 81.5% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * 18 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown MALAYSIA Total population (2015) 30 485 200 Births (2015) 511 865 Surviving infants (2015) 511 865 Urban population (2015) 75% HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1997-2007 Nationwide 6-9 years School based 193 717 0.40% MoH Malaysia 2011 2003 Nationwide 7 years School based 12 269 0.40% Ng Med Microb Imm 2005 2007 Nationwide 7-9 years Community based 1735 0.30% MoH Malaysia 2008 2009 Nationwide 9 years School based 2938 0.2% (0% - 0.3%) MoH Malaysia 2011 2009 Nationwide 10 years School based 3265 0.4% (0.2% - 0.6%) MoH Malaysia 2011 Status of verifying prevalence targets Verification started: March 2011 Decision: <1% in children Decision date: July 2011 98.1% 1.4% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Surviving infants was from the United Nations World Population Prospects the 2015 revision; Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 19 FEDERATED STATES OF MICRONESIA Total population (2015) 102 624 Births (2015) 2 290 Surviving infants (2015) 2 243 Urban population (2015) 22% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-HepB-IPV Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1989 National 2 years 16 391 not reported 84% not reported Manea PH Reports 1992 1992 Chuuk 2 years 544 not reported 40% not reported Mahoney Pac Hth Dialog 1996 1994 Pohnpei 3-4 years 364 not reported 82% not reported Mahoney Pac Hth Dialog 1996 2000 Chuuk 2-6 years 365 50% 87% not reported Bialek ISVHLD P351 2006 2005 Pohnpei 2-9 years 478 87% 90% not reported Bialek Ped Infect Dis 2010 2005 National 2-9 years 432 75% 91% not reported Bialek ISVHLD P351 2006 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2005 Chuuk 2-6 years Hospital based 362 2.5% Bialek PID 2010 2005 Pohnpei 2-6 years Hospital based 478 1.5% Bialek PID 2010 Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 80.0% 20.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 20 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown MONGOLIA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2001 National 12-23 months 1255 not reported not reported 89% Mongolia, Child and Development survey-2000 (MICS-2), 2001 2004 National 4-6 years 5894 95% 73% not reported MoH Mongolia 2011 2004 National 8 years 1145 65% 60% not reported Davaalkham J Epid 2007 2005 National 12-23 months 724 not reported not reported 93% Mongolia Child and Development 2005 Survey (MICS-3): DTP3-92% by 12M 2010 National 12-23 months 944 97% not reported 92% MICS : HepB BD 96.7% by 12M; DPT3 92.1% by 12M 2013 National 12-23 months 1180 99% 98% 98% Mongolia Social Indicator Sample Survey: HepB BD 93.1%, HepB3 92.5%, DTP3 92.5% by 12M 2013 National 24-35 months 1236 97% 96% 96% Mongolia Social Indicator Sample Survey :HepB BD 86%, HepB3 84.2%, DTP3 84.2% by 12M Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2004 National 7-12 years School based 1145 5.2% Davaalkham PI 2007 2009 National 4 years Community based 5894 0.34% MoH Mongolia 2011 Total population (2015) 3 129 495 Births (2015) 81 715 Surviving infants (2015) 79 647 Urban population (2015) 72% HepB3 introduced nationwide 1991 HepB birth dose introduced 1991 Current schedule 0, 2 months, 3 months, 4 months HepB3 type DTP-Hib-HepB Status of verifying prevalence targets Verification started: April 2012 Decision: <1% in children Decision date: July 2012 99.5% 0.2% 0.2% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 21 NAURU Total population (2015) 10 084 Births (2015) 377 Surviving infants (2015) 372 Urban population (2015) 100% HepB3 introduced nationwide 1983 HepB birth dose introduced Yes, introduction year unknown Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 97.4% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * 22 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown NEW CALEDONIA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes Total population (2014) 268 767 Births (2014) 4 425 Surviving infants (2014) 4 352 Urban population (2015) 70% HepB3 introduced nationwide 1989 HepB birth dose introduced Yes, introduction year unknown Current schedule 0, 1 month, 6 months HepB3 type Monovalent Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 87.6% 4.4% 8.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 23 NEW ZEALAND Total population (2015) 4 649 700 Births (2015) 61 328 Surviving infants (2015) 61 038 Urban population (2015) 86% HepB3 introduced nationwide 1985 HepB birth dose introduced If born to HBsAg+ mothers Current schedule 6 weeks, 3 months, 5 months HepB3 type DTP-Hib-HepB-IPV Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2005 National 12 months 1563 72% 82% 85% MoH; 87% HepB3 by 2 years Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2009 North Islands 6 years Health facility 466 0.2% (0.0% - 1.2%) Weir R. MoH New Zealand 2009 Status of verifying prevalence targets Verification started: April 2012 Decision: <1% in children Decision date: September 2012 95.3% 4.7% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. * 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 24 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown NIUE Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2015 Nationwide 5-12 years School based 183 0.0% Niue Health Department 2015 Total population (2015) 1776 Births (2015) 30 Surviving infants (2015) 30 Urban population (2015) 43% HepB3 introduced nationwide 1986 HepB birth dose introduced Yes, introduction year unknown Current schedule 0, 6 weeks, 3 months, 5 months HepB3 type DTP-Hib-HepB-IPV Status of verifying prevalence targets Verification started: November 2015 Decision: n.a. Decision date: n.a. 100.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 25 PALAU Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2003 National 10-11 years 192 100% 85% not reported Bialek ISVHLD P351 2006 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2003 Nationwide 10-11 years Community based 192 0% Bialek ISVHLD P351 2006 2008 Main Island 5-7 years School based 143 0% MoH Palau 2013 Total population (2015) 7261 Births (2015) 301 Surviving infants (2015) 301 Urban population (2015) 87% HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 6 weeks, 6 months HepB3 type DTP-HepB-IPV and monovalent Status of verifying prevalence targets Verification started: January 2013 Decision: <1% in children Decision date: May 2013 100.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * 26 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown PAPUA NEW GUINEA Total population (2015) 8 235 782 Births (2015) 263 545 Surviving infants (2015) 248 576 Urban population (2015) 13% HepB3 introduced nationwide 1989 HepB birth dose introduced ~2003 Current schedule 0, 1 month, 2 months, 3 months HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2005-2006 National 12-23 months 783 not reported not reported 71% National Immunization Coverage Survey 2005-2006 National 12-23 months 774 not reported 73% not reported National Immunization Coverage Survey Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1989-1990 Port Moresby 3-5 months Hospital Based 31 13% Nemba ATPaed. 1993 2012-2013 National 4-6 years Community based 2109 2.3% Kitau ASTMH 2015 Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 40.0% 60.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 27 PHILIPPINES Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1998-1999 National 12-23 months 1474 not reported not reported 81% DHS Survey: DTP3 79% by 12 months 2000 National 12-23 months 2227 not reported 32% 80% Philippines, Maternal and Child Health Survey 2000 2002 National 12-23 months 1885 not reported not reported 81% Philippines, Maternal and Child Health Survey 2002 2003 National 12-23 months 1348 not reported not reported 79% DHS Survey: DTP3 75% by 12 months 2008 National 12-23 months 1286 not reported 80% 86% DHS Survey (NDHS) 2008: by 12 months (HepB3 76%, DTP3 83%) 2013 National 12-23 months 1397 not reported 78% 86% DHS Survey, 2013: by 12 months (HepB3 74%, DTP3 85%) Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2013 24 of 81 provinces 5-6 years Community-based 2704 0.33% (0.15% - 0.73%) The Philippine Department of Health 2016 Total population (2015) 101 771 950 Births (2015) 2 747 843 Surviving infants (2015) 2 679 147 Urban population (2015) 44% HepB3 introduced nationwide 1991 HepB birth dose introduced 2007 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 44.0% 18.2% 37.8% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * 28 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown REPUBLIC OF KOREA Total population (2015) 51 529 338 Births (2015) 435 969 Surviving infants (2015) 433 930 Urban population (2015) 83% HepB3 introduced nationwide 1983 HepB birth dose introduced 1983 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2008 National 0-6 years 1026 100% 93% 95% CDC Korea; provided during 2012 TAG 2009 National 19-35 months not reported not reported 99% 99% 2009 Korea National Immunization Survey (Confirmation method NA) 2011 National 0-3 years 7040 99% 98% 93% CDC Korea; provided during 2012 TAG Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2005 Nationwide 10-14 years Community based 594 0.2% (0.0% - 0.6%) CDC Korea 2008 2007 Nationwide 4-6 years Hospital based 2920 0.2% (0.0% - 0.4%) CDC Korea 2008 2014 Nationwide 10-18 years Community based 510 0.1% KNHANES 2014 Status of verifying prevalence targets Verification started: January 2008 Decision: <1% in children Decision date: June 2008 99.9% 0.1% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 29 REPUBLIC OF THE MARSHALL ISLANDS Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2006 National 0-24 months 115 not reported 86% 65% RMI Community Survey2006: confirmation method by card only 2007 Majuro, Ebeye 5-9 years 331 49% 93% not reported Bialek Ped Infect Dis 2010 2007 National not reported 214 not reported not reported 17% (for age 48-59M); 32% (for age 36-47M) DHS Survey 2007: DTP3 by 12 months 2007 National 24-35 months 207 not reported not reported 32% DHS Survey 2007: DTP3 by 12 months 2007 National 12-23 months 249 not reported not reported 48% DHS Survey; DTP3 38% by 12 months Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2007 Majuro, Ebeye 5-9 years School based 331 1.8% (0.4% - 3.3%) Bialek PID 2010 Total population (2015) 54 880 Births (2015) 1 140 Surviving infants (2015) 1 135 Urban population (2015) 73% HepB3 introduced nationwide 1990s HepB birth dose introduced 1998 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-HepB-IPV Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 97.0% 2.0% 1.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * 30 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown SAMOA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2009 National 12-24 months 321 70% not reported not reported DHS Survey 2009 National 18-29 months 321 not reported not reported 38% DHS Survey:37% DTP3 by 12 months 2014 National 48-59 months 559 75% 45% 45% DHS Survey; by 12 months 2014 National 36-47 months 605 81% 50% 50% DHS Survey; by 12 months 2014 National 24-35 months 680 82% 54% 54% DHS Survey; by 12 months 2015 National 12-23 months 674 84% 64% 64% DHS Survey; by 12 months 2015 National 18-29 months 666 83% 64% 64% DHS Survey; by 18 months 83% HepB, 63% HepB3 and 63% DTP3 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2014 Nationwide 5-6 years School based 1776 0.11% MoH Samoa 2015 Total population (2015) 192 598 Births (2015) 5 915 Surviving infants (2015) 5 624 Urban population (2015) 19% HepB3 introduced nationwide 1990 HepB birth dose introduced Yes, introduction year unknown Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 81.0% 19.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 31 SINGAPORE Total population (2014) 3 870 739 Births (2014) 33 087 Surviving infants (2014) 33 087 Urban population (2015) 100% HepB3 introduced nationwide 1985 HepB birth dose introduced 1987 Current schedule 0, 1 month, 5-6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2007 National 2 years 31 778 not reported 94%-96% 97% Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1998-1999 National 0-4 years not reported 229 0% Epi News Bull SNG 2000 2008-2010 Two public hospitals 1-17 years Hospital based 1200 0.3% (0.1%-0.9%) Ang J Med Virol 2013 Status of verifying prevalence targets Verification started: April 2015 Decision: <1% in children Decision date: October 2015 99.7% 0.3% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 32 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown SOLOMON ISLANDS Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2006-2007 National 48-59 months 477 not reported not reported 72% DHS Survey (DTP3 by 12 months) 2006-2007 National 36-47 months 515 not reported not reported 81% DHS Survey (DTP3 by 12 months) 2006-2007 National 24-35 months 533 not reported not reported 80% DHS Survey (DTP3 by 12 months) 2006-2007 National 12-23 months 535 not reported not reported 88% DHS Survey (87% DTP3 by 12 months) Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1999 Guadalcanal Islands 0-9 years Hospital based 115 13% Furusyo Am J Trop 1999 Total population (2015) 592 206 Births (2015) 18 450 Surviving infants (2015) 17 897 Urban population (2015) 22% HepB3 introduced nationwide 1990 HepB birth dose introduced ~2005 Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 85.0% 1.0% 14.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 33 TOKELAU Total population (2015) 1383 Births (2015) 30 Surviving infants (2015) 29 Urban population (2015) 0% HepB3 introduced nationwide 1990 HepB birth dose introduced 1990 Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2014 Nationwide 6-12 years School based 171 0.0% MoH Tokelau 2015 Status of verifying prevalence targets Verification started: May 2015 Decision: <1% in children Decision date: July 2016 100.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * 34 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown TONGA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2003 National 12-23 months 114 not reported 94% 96% Evaluation of Immunization Program of the Kingdom of Tonga 2005 Tongatapu hospital 6-59 months 445 92% 98% 98% Danielsson Vaccine 2009 2012 National 48-59 months 302 not reported 61% 61% DHS Survey (HepB3 and DTP3 by 12 months) 2012 National 36-47 months 334 not reported 59% 59% DHS Survey (HepB3 and DTP3 by 12 months) 2012 National 24-35 months 383 not reported 60% 60% DHS Survey (HepB3 and DTP3 by 12 months) 2012 National 12-23 months 307 not reported 66% 66% DHS Survey (65% HepB3 and 65% DTP3 by 12 months) Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1998 Large Towns 12-24 months Hospital based 211 3.8% Wilson Vaccine 2000 2005 Main Island 6-59 months Hospital based 375 0.8% (0.2% - 2.5%) Danielsson Vaccine 2009 Total population (2014) 109 418 Births (2014) 2 744 Surviving infants (2014) 2 917 Urban population (2014) 24% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB Status of verifying prevalence targets Verification started: May 2011 Decision: <2% in children Decision date: January 2012 98.0% 0.4% 1.6% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 35 TUVALU Total population (2012) 10 837 Births (2012) 265 Surviving infants (2012) 265 Urban population (2012) 60% HepB3 introduced nationwide Yes, introduction year unknown HepB birth dose introduced Yes, introduction year unknown Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2007 National 48-59 months 75 not reported not reported 59% DHS Survey (DTP3 by 18 months) 2007 National 36-47 months 84 not reported not reported 57% DHS Survey (DTP3 by 18 months) 2007 National 24-35 months 89 not reported not reported 60% DHS Survey (DTP3 by 18 months) 2007 National 18-29 months 80 not reported not reported 62% DHS Survey (60% DTP3 by 18 months) Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1976 Fanafuti 10-19 years Community based 181 11% Gust JID 1979 Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 100.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * 36 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown VANUATU Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2007 National 12-23 months 359 not reported 59% 63% MICS; by 12 months 55% HepB3, 58% DTP3 2013 National 12-23 months 303 not reported 55% 55% DHS Survey; by 12 months 49% HepB3, 49% DTP3 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1988 Emao or Nguna 12-18 months Community based 112 17% Maher Med J Aust 1991 1998 Large Towns 12-24 months Hospital based 132 3.0% Wilson Vaccine 2000 Total population (2015) 267 184 Births (2015) 8 283 Surviving infants (2015) 8 051 Urban population (2015) 26% HepB3 introduced nationwide 1989–1990 HepB birth dose introduced 1989–1990 Current schedule 0, 6 weeks, 10 weeks,14 weeks HepB3 type DTP-Hib-HepB Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 80.0% 20.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 37 VIET NAM Total population (2015) 91 583 000 Births (2015) 1 753 504 Surviving infants (2015) 1 753 504 Urban population (2015) 34% HepB3 introduced nationwide 1997 HepB birth dose introduced 2005 Current schedule 0, 2 months, 3 months, 4 months HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2002 National 12-24 months 457 not reported not reported 72% DHS Survey 2006 National 12-23 months 555 not reported 34% 79% MICS; 32% HepB3 and 76% DTP3 by 12 months 2002-2003 National 12-23 months 457 not reported not reported 72% DHS Survey 2010-2011 National 12-23 months 759 not reported 56% 74% MICS; 53% HepB3 and 73% DTP3 by 12 months 2014 National 24-35 months 641 71% 92% 93% MICS; 71% HepB BD, 92% HepB3 and 93% DTP3 by 12 months 2014 National 12-23 months 790 78% 87% 89% MICS; 78% HepB BD, 87% HepB3 and 89% DTP3 by 12 months Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1998 Thanh Hoa 9-18 months Community based 536 12.5% Hipgrave AJTMH 2003 2011 National 3-4 years Community based 3426 1.6% (1.25%-2.15%) Nguyen Vaccine 2014 2011 National 5-7 years Community based 1738 2.2% (1.47%-3.14%) Nguyen Vaccine 2014 2011 National 8-11 years Community based 1740 3.6% (2.80%-4.71%) Nguyen Vaccine 2014 Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 94.4% 5.6% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 * 38 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown WALLIS AND FUTUNA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2011 National 7-12 years 442 not reported 94% not reported Data from national serosurvey Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2012 National 9-11 years School-based 428 0.93% PRELIMINARY DATA Total population (2015) 12 197 Births (2015) 157 Surviving infants (2015) 156 Urban population (2015) 0% HepB3 introduced nationwide Yes, introduction year unknown HepB birth dose introduced Yes, introduction year unknown Current schedule 0, 1 month, 6 months HepB3 type Monovalent Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 100.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3
Expanded Programme on Immunization Regional Office for the Western Pacific World Health Organization P.O. Box 2932, 1000 Manila, Philippines Tel. no. (+63 2) 5288001 Fax. no. (+63 2) 5211036, 5260279 wproepi@who.int
Regional Progress Hepatitis B vaccination coverage, 1990 – 2015 0 10 20 30 40 50 60 70 80 90 100 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 V ac ci n at io n c o ve ra ge ( % ) Year of birth Hepatitis B vaccine birth dose Hepatitis B vaccine 3rd dose Source: WHO and UNICEF Joint Reporting Form on Immunization 1
Regional Progress Regional Progress: Status of the 2017 Hepatitis B Control Milestone of <1% HBsAg Prevalence among 5 year old children The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. © WHO Regional Office for the Western Pacific 2016. All rights reserved 2
Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 3 AMERICAN SAMOA Total population (2015) 55 538 Births (2011) 1 287 Surviving infants (2011) 1 278 Urban population (2015) 87% HepB3 introduced nationwide 1986-1987 HepB birth dose introduced 1991 Current schedule 0, 1 month, 12 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1990 National 3–4 years 95 not reported 82% not reported Mahoney Pac Hth Dialog 1996 1995 National 7-8 years 432 75% 91% not reported Bialek ISVHLD P351 2006 1996 National 7-8 years 435 not reported 87% not reported Mahoney Pac Hth Dialog 1996 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1991 Tutuila 3-4 years Community based 93 2.2% Mahoney JID 2009 1995 Nationwide 7-8 years Community based 432 0.5% Bialek ISVHLD P351 2006 2011 Nationwide 6 years School based 562 0.2% Govt American Samoa 2012 Status of verifying prevalence targets Verification started: February 2013 Decision: <1% in children Decision date: October 2014 99.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population was from the United Nations World Population Prospects the 2015 revision; Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3
4 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown AUSTRALIA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2007 National 12 months 280 874 not reported 94% 92% From National Health Insurance covering 99% of population Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2002 Nationwide 1-9 years Hospital based 249 0.4% (0.0% - 2.2%) Gidding Vaccine 2007 Total population (2015) 23 968 973 Births (2015) 317 650 Surviving infants (2015) 314 448 Urban population (2015) 89% HepB3 introduced nationwide 2000 HepB birth dose introduced 2000 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-Hib-HepB-IPV Status of verifying prevalence targets Verification started: June 2012 Decision: <1% in children Decision date: December 2012 99.1% 0.9% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic ts 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Total population, births and surviving infants were from the United Nations World Population Prospects the 2015 revision; Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 *
Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 5 BRUNEI DARUSSALAM Total population (2015) 417 200 Births (2015) 6 699 Surviving infants (2015) 6 455 Urban population (2015) 77% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-Hib-HepB-IPV Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2011 National 8-9 years School based 4513 0.09% MoH Brunei 2012 Status of verifying prevalence targets Verification started: March 2013 Decision: <1% in children Decision date: June 2013 99.8% 0.1% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3
6 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown CAMBODIA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2005 National 12-23 months 1517 not reported not reported 78% DHS Survey 2009 National 12-23 months 1068 61% not reported 56% Cambodia Socio-Economic Survey 2009 (confirmation method only by card) 2010 National 12-23 months 1614 73% 84% 84% DHS Survey:HepB BD 73%, HepB3 85%, DTP3 85% by 12 months 2014 National 12-23 months 1460 83% 84% 84% DHS Survey:HepB BD 83%, HepB3 82%, DTP3 82% by 12 months Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2001 Kg Chhnang 9-17 months Hospital based 900 2.7% Report MoH/PATH/AIHI 2006 Nationwide 5 years Community based 1558 3.5% (2.4% - 4.8%) Soeung AMTH 2009 2011 Urban, Rural, Remote 4-5 years Community based 2429 0.3%, 1.4%, 3.5% Mao Vaccine 2013 Total population (2015) 14 892 374 Births (2015) 381 245 Surviving infants (2015) 344 014 Urban population (2015) 93% HepB3 introduced nationwide 2005 HepB birth dose introduced 2005 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 54.0% 17.0% 29.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 *
Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 7 CHINA Total population (2015) 1 374 620 000 Births (2015) 16 550 000 Surviving infants (2014) 16 152 165 Urban population (2015) 21% HepB3 introduced nationwide 1992 HepB birth dose introduced 1992 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2004 National 12-23 months 171 188 not reported 85% not reported The National EPI Evaluation Report 2004 (Confirmation method by card only); 90% HepB3 by 12 months 2006 National 1 year 3636 93% 83% not reported Liang JID 2009; 2005 birth cohort 2008 National 12-23 months 9762 not reported 93% 91% Analysis Report of National Health Services Survey in China Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2006 Nationwide 1-4 years Community based 16 376 1.0% (0.8% - 1.2%) Liang Vaccine 2009 2006 Nationwide 5 years Community based 2215 1.1% (0.4% - 1.8%) Liang JID 2009 2006 Nationwide 6 years Community based 2356 0.9% (0.4% - 1.5%) Liang JID 2009 Status of verifying prevalence targets Verification started: February 2012 Decision: <1% in children Decision date: June 2012 96.3% 3.7% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3
Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 11 COOK ISLANDS Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2012 7 of 11 islands 6 years School based 265 0% MoH Cook Islands 2013 Total population (2015) 15 052 Births (2015) 234 Surviving infants (2015) 232 Urban population (2015) 56% HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 6 weeks, 3 months, 5 months HepB3 type DTP-Hib-HepB Status of verifying prevalence targets Verification started: January 2013 Decision: <1% in children Decision date: October 2013 99.6% 0.4% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 *
12 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown FIJI Total population (2015) 933 073 Births (2015) 20 236 Surviving infants (2015) 20 072 Urban population (2015) 75% HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1999 National 12-23 months not reported not reported 94% 92% Fiji National EPI Survey 2005 National 12-23 months 630 not reported 92% 83% Fiji Immunization Coverage Survey Report 2008 National 15-26 months 1200 86% 99% 99% Fiji National Immunisation Coverage Survey Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1998 Large Towns 12-24 months Hospital based 285 0.7% Wilson Vaccine 2000 2008 Sub-national 6 months-5 years Community based 428 0% WHO:RS/2009/GE/23(JPN) Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 99.8% 0.2% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3
Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 13 FRENCH POLYNESIA Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1988 Austral Island 0-11 months Community based 957 2.1% B Trans R Soc Trop 1990 2013-2014 Nationwide 6-7 years School based 1196 0.0% (0.0%-0.5%) Patel Vaccine 2016 Total population (2015) 271 800 Births (2015) 4 146 Surviving infants (2015) no data Urban population (2015) 54% HepB3 introduced nationwide 1992 HepB birth dose introduced 1992 Current schedule 0, 2 months, 10 months HepB3 type DTP-Hib-HepB-IPV Status of verifying prevalence targets Verification started: February 2016 Decision: <1% in children Decision date: October 2016 99.0% 1.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 *
14 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown GUAM Total population (2015) 161 785 Births (2015) 3 367 Surviving infants (2015) 3 319 Urban population (2015) 56% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 1-2 months, 6-18 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2015 National 6 years School based 1484 0.0% Guam DoH & Social Services 2015 Status of verifying prevalence targets Verification started: October 2015 Decision: <1% in children Decision date: July 2016 87.2% 0.6% 12.2% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3
8 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown HONG KONG SAR (CHINA) Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2009 National 2-5 years 6248 not reported ≥99.5% >99.8% MoH Hong Kong 2011 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2006 Nationwide 1-4 years Laboratory based 196 1% MoH Hong Kong 2011 2009 Nationwide 12-15 years School based 1913 0.8% (0.4% - 1.2%) MoH Hong Kong 2011 Total population (2015) 7 305 700 Births (2015) 59 901 Surviving infants (2015) no data Urban population (2015) 95% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Status of verifying prevalence targets Verification started: February 2011 Decision: <1% in children Decision date: July 2011 100.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 *
Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 15 JAPAN Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1989 Okinawa 1-4 years School based 1529 0.1% Hayashi Int J Epi 1990 1995-1996 Nationwide 16-19 years Blood Donors 107 879 0.4% (0.4% - 0.5%) Furusyo AMTM 1998 1995-2000 Nationwide 16-19 years Blood Donors 582 415 0.23% (0.22% - 0.24%) Tanaka Intervirol 2004 2009 Iwate prefecture 5-9 years School based 17 363 0.0% (0.00%-0.04%) Tanaka Intervirol 2011 Total population (2015) 126 942 000 Births (2015) 1 037 064 Surviving infants (2015) 1 013 979 Urban population (2015) 100% HepB3 introduced nationwide Scheduled to start in Oct 2016 HepB birth dose introduced If born to HBsAg+ mothers Current schedule 2 months, 3 months, 7 months HepB3 type Monovalent Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 99.8% 0.2% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3
16 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown KIRIBATI Total population (2015) 114 104 Births (2015) 3 340 Surviving infants (2015) 3 180 Urban population (2015) 44% HepB3 introduced nationwide 1995 HepB birth dose introduced 1990 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2009 National 48-59 months 181 not reported not reported 32% DHS Survey; by 12 months 2009 National 36-47 months 200 not reported not reported 42% DHS Survey; by 12 months 2009 National 24-35 months 202 not reported not reported 50% DHS Survey; by 12 months 2009 National 12-23 months 233 not reported 61% 61% DHS Survey: HepB3 58%, DTP3 58% by 12 months Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1998 Large Towns 12-24 months Hospital based 156 3.8% Wilson Vaccine 2000 2014 National 5-9 years Community based 1249 3.3% MoH Kiribati 2015 Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 81.9% 16.4% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 *
Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 17 LAO PEOPLE’S DEMOCRATIC REPUBLIC Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2006 National 12-23 months 828 not reported not reported 41% Lao PDR Multiple Indicator Cluster Survey 2006 Final Report; DTP3 32% by 12 months 2011-2012 National 12-23 months 2141 37% 56% 56% Lao Social Indicator Survey (LSIS), (MICS / DHS Survey): HepB BD 37%, HepB3 52%, DTP3 52% by 12 months 2015 National 12-23 months 5981 72% 81% 81% National Immunization Survey Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2012 National 5-9 years Community based 965 1.7% (0.8%-2.6%) Xeuatvongsa PloS ONE 2014 Total population (2015) 6 949 000 Births (2015) 194 026 Surviving infants (2015) 183 962 Urban population (2015) 39% HepB3 introduced nationwide 2001 HepB birth dose introduced ~2004 Current schedule 0, 6 weeks, 10 weeks, 14 weeks HepB3 type DTP-Hib-HepB Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 12.8% 5.7% 81.5% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 *
Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 9 MACAO SAR (CHINA) Total population (2015) 646 800 Births (2015) 7 055 Surviving infants (2015) 7 055 Urban population (2015) 100% HepB3 introduced nationwide 1984 HepB birth dose introduced 1989 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2003 National 6-9 years School based 437 0% (0% - 0.7%) MoH Macao 2008 Status of verifying prevalence targets Verification started: April 2008 Decision: <1% in children Decision date: August 2008 100.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 *
18 Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown MALAYSIA Total population (2015) 30 485 200 Births (2015) 511 865 Surviving infants (2015) 511 865 Urban population (2015) 75% HepB3 introduced nationwide 1989 HepB birth dose introduced 1989 Current schedule 0, 1 month, 6 months HepB3 type Monovalent Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 1997-2007 Nationwide 6-9 years School based 193 717 0.40% MoH Malaysia 2011 2003 Nationwide 7 years School based 12 269 0.40% Ng Med Microb Imm 2005 2007 Nationwide 7-9 years Community based 1735 0.30% MoH Malaysia 2008 2009 Nationwide 9 years School based 2938 0.2% (0% - 0.3%) MoH Malaysia 2011 2009 Nationwide 10 years School based 3265 0.4% (0.2% - 0.6%) MoH Malaysia 2011 Status of verifying prevalence targets Verification started: March 2011 Decision: <1% in children Decision date: July 2011 98.1% 1.4% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Surviving infants was from the United Nations World Population Prospects the 2015 revision; Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 *
Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 29 REPUBLIC OF THE MARSHALL ISLANDS Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 2006 National 0-24 months 115 not reported 86% 65% RMI Community Survey2006: confirmation method by card only 2007 Majuro, Ebeye 5-9 years 331 49% 93% not reported Bialek Ped Infect Dis 2010 2007 National not reported 214 not reported not reported 17% (for age 48-59M); 32% (for age 36-47M) DHS Survey 2007: DTP3 by 12 months 2007 National 24-35 months 207 not reported not reported 32% DHS Survey 2007: DTP3 by 12 months 2007 National 12-23 months 249 not reported not reported 48% DHS Survey; DTP3 38% by 12 months Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2007 Majuro, Ebeye 5-9 years School based 331 1.8% (0.4% - 3.3%) Bialek PID 2010 Total population (2015) 54 880 Births (2015) 1 140 Surviving infants (2015) 1 135 Urban population (2015) 73% HepB3 introduced nationwide 1990s HepB birth dose introduced 1998 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-HepB-IPV Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 97.0% 2.0% 1.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization *HepB3 vaccination coverage when available, otherwise graph represents DPT3 coverage. 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3 *
Demographics Hepatitis B vaccine Vaccination coverage surveys Hepatitis B vaccination coverage 2015 Districts by coverage categories 2012 Neonatal deliveries Hepatitis B serological surveys WHO verification Health facility Home with SBA Home with no SBA Unknown 19 FEDERATED STATES OF MICRONESIA Total population (2015) 102 624 Births (2015) 2 290 Surviving infants (2015) 2 243 Urban population (2015) 22% HepB3 introduced nationwide 1988 HepB birth dose introduced 1988 Current schedule 0, 2 months, 4 months, 6 months HepB3 type DTP-HepB-IPV Survey year Location Ages enrolled Sample size HepB BD % HepB3 % DTP3 % Reference/Notes 1989 National 2 years 16 391 not reported 84% not reported Manea PH Reports 1992 1992 Chuuk 2 years 544 not reported 40% not reported Mahoney Pac Hth Dialog 1996 1994 Pohnpei 3-4 years 364 not reported 82% not reported Mahoney Pac Hth Dialog 1996 2000 Chuuk 2-6 years 365 50% 87% not reported Bialek ISVHLD P351 2006 2005 Pohnpei 2-9 years 478 87% 90% not reported Bialek Ped Infect Dis 2010 2005 National 2-9 years 432 75% 91% not reported Bialek ISVHLD P351 2006 Survey year Location Ages enrolled Sampling base Sample size HBsAg prevalence (95%CI) Reference/Notes 2005 Chuuk 2-6 years Hospital based 362 2.5% Bialek PID 2010 2005 Pohnpei 2-6 years Hospital based 478 1.5% Bialek PID 2010 Status of verifying prevalence targets Verification started: pending Decision: n.a. Decision date: n.a. 80.0% 20.0% 0 20 40 60 80 100 <50% <50%-79% 80%-89% 90%-94% >94% % D is tr ic t 2 0 1 5 HepB3 Timely HepB BD Abbreviations: DTP3: 3rd dose of Diphteria, Tetanus and Pertusis vaccine; HepB3: at least 3 doses of hepatitis B vaccine; HBsAg: hepatitis B surface antigen; SBA: Skilled Birth Attendant; Timely HepB BD: birth dose within 24 hours Sources: Urban Population was derived from World Bank; 2012 Neonatal deliveries was derived from the Western Pacific Country Health Information Profiles; Unless otherwise noted in the section marked References/Notes, all remaining data was derived from the WHO and UNICEF Joint Reporting Form on Immunization 0 20 40 60 80 100 2011 2012 2013 2014 2015 V a c c in a ti o n C o v e ra g e ( % ) Timely HepB BD Any HepB BD HepB3